SC
EPRX

Scotia Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Scotia Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.24M Buy
1,342,178
+55,995
+4% +$451K 0.03% 246
2025
Q4 		$9.6M Buy
1,286,183
+8,298
+0.6% +$51.1K 0.04% 213
2025
Q3 		$7.25M Sell
1,277,885
-14,104
-1% -$76.7K 0.03% 244
2025
Q2 		$6.98M Sell
1,291,989
-260,690
-17% -$1M 0.03% 235
2025
Q1 		$5.07M Buy
1,552,679
+160,960
+12% +$556K 0.03% 264
2024
Q4 		$4.26M Sell
1,391,719
-4,562
-0.3% -$13.5K 0.02% 293
2024
Q3 		$3.49M Buy
1,396,281
+29,230
+2% +$76.9K 0.02% 328
2024
Q2 		$3.5M Buy
+1,367,051
New +$3.8M 0.02% 308

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Scotia Capital's EPRX Position: Q1 2026 in Review

Scotia Capital increased its Eupraxia Pharmaceuticals (EPRX) stake by 4.4% in Q1 2026, buying an estimated $451K and bringing the position to 1,342,178 shares worth $7.24M. The position accounts for 0.03% of the portfolio, ranked #246.

Scotia Capital first reported a position in EPRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $9.6M in Q4 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Scotia Capital held 1,342,178 shares of Eupraxia Pharmaceuticals worth $7.24M as of Q1 2026.
  • Scotia Capital bought 55,995 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $451K.
  • Eupraxia Pharmaceuticals made up 0.03% of Scotia Capital's portfolio in Q1 2026, its #246 holding.
  • Scotia Capital first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Scotia Capital's Eupraxia Pharmaceuticals position peaked at $9.6M in Q4 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Scotia Capital's 13F filing for Q1 2026, filed 13 May 2026.